CUPRIOR Filmtabl 150 mg 72 Stk

Cuprior, Filmtabletten

Quelle		
Compendium	CUPRIOR Filmtabl 150 mg	compendium.ch®
SAI	CUPRIOR Filmtabl 150 mg 72 Stk	refdata

Medicinal Product			
MPID	CH-7640109110007-6771901		
Approved Dose Form (EXT)	FILM	Filmtabletten	

Product Classification		
ATC	A16AX12	
Heilmittelcode	S – Synthetika	

Medicinal Product Name		
Type (EXT)	Original	
Full Name	Cuprior 150 mg, Filmtabletten	
Invented Name Part	Cuprior	
Pharmaceutical Dose Form Part	Filmtabletten	
Strength Part	150 mg	
Delimiter	,	

Country / Language			
Language	de	Deutsch	

Medicinal Product Name			
Type (EXT)	BAG		
Full Name	CUPRIOR Filmtabl 150 mg		
Invented Name Part	CUPRIOR		
Pharmaceutical Dose Form Part	Filmtabl		
Strength Part	150 mg		
Country / Language			
Language	de	Deutsch	

Marketing Authorisation (Medicinal Product)			
Marketing Authorisation Type (EXT)	Marktzulassung		
Marketing Authorisation Number	6771901		
Legal Status of Supply	B	Abgabe auf ärztliche oder tierärztliche Verschreibung (B)	
Authorisation Status	Z	Zugelassen	
Authorisation Status Date	21.01.2021		
Validity Period End	20.01.2026		
Date of First Authorisation	21.01.2021		

Marketing Authorisation Holder (Organisation)		
Name	Curatis AG	
GLN	7640109110007	

Hinweis: Pack Size, 72 Filmtabletten

Packaged Medicinal Product		
PCID	CH-7640109110007-6771901-001	
Package Description	CUPRIOR Filmtabl 150 mg 72 Stk	
Pack Size (EXT)	72 Tablette(n)	

Data Carrier Identifier			
GTIN (Code System)	7680677190018		

Packaged Item (Container)			
Package Item (Container) Type	30009000	Box	
Package Item (Container) Quantity	1		
Material	Karton		

Packaged Item (Container)			
Package Item (Container) Type	30007000	Blister	
Package Item (Container) Quantity	Unknown		
Material	Aluminium, Aluminium		

Packaged Item (Manufactured Item)			
Manufactured Item Quantity	72	Tabletten (per box)	

Marketing Authorisation (Packaged Medicinal Product)			
Marketing Authorisation Type	tbd		
Marketing Authorisation Number	67719001		
Legal Status of Supply	B	Abgabe auf ärztliche oder tierärztliche Verschreibung (B)	
Authorisation Status	Z	Zugelassen	
Authorisation Status Date	21.01.2021		
Validity Period End	20.01.2026		

Shelf Life / Storage			
Shelf Life Type	100000073403	Closed Package	
Shelf Life Time Period	24 mo		
Special Precautions of Storage	NO30	Nicht über 30°C lagern	

Manufactured Item			
Manufactured Dose Form	10221000	Filmtablette	
Unit of Presentation	15054000	Tablette	

Ingredient (Manufactured Item) / Substance / Strength / Reference Strength			
Ingredient Role	WIRKS	Wirkstoff	
Substance	SJ76Y07H5F	Trientinum	
Strength (presentation)	150 mg (per UoP)		

Ingredient (Manufactured Item) / Substance / Strength / Reference Strength			
Ingredient Role	WIRKS	Wirkstoff	
Substance		Trientini tetrahydrochloridum	

Ingredient (Manufactured Item) / Substance / Strength / Reference Strength			
Ingredient Role	HNIDK	Hilfsstoff	
Substance	3OWL53L36A	Mannitolum	
	ETJ7Z6XBU4	Silica colloidalis anhydrica	
	R8WTH25YS2	Glyceroli dibehenas	
	532B59J990	Poly (alcohol vinylicus)	
	7SEV7J4R1U	Talc Talcum	
	15FIX9V2JP	TITANII DIOXIDUM CL 77891 E 171	
	HYE7O27HAO	Glyceroli monocaprylocapras	
	EX438O2MRT	E 172 (flavum) YELLOW LAKE CLF 3076 (E104 AND E172)	
	368GB5141J	Natrii laurilsulfas	
	9NEZ333N27	0.057 mg Natrium	

Pharmaceutical Product / Route of Administration			
Administrable Dose Form	10221000	Filmtablette	
Unit of Presentation	15054000	Tablet	
Route of Administration	20053000	Oral use	
Methode of Administration (Swissmedic)	200000002052	Swallowing	

Therapeutic Indication			
Indication as	10061091	Copper metabolism disorder (Morbus Wilson)	
Intended Effect	200000003194	Therapie	